What if you had an unfair advantage in clinical trial planning?

De-risk your clinical trial before day one. Turn uncertainty into strategy with predictive intelligence that surfaces risks before they become problems.

85% Success probability

Breakthrough science deserves breakthrough processes

0
of trials undergo avoidable amendments
0
wasted on rework
0
lost to inefficiency

Promising treatments are delayed for the wrong reasons. Let us change that.

How it works

Ingest data

Historical trial data, regulatory documents, and industry benchmarks

AI analysis

Advanced algorithms identify patterns and predict potential risks

Deliver insights

Clear, actionable recommendations to setup your trial for success

Learn from every trial
but your own

Turn the industry's collective experience into your competitive advantage. See what worked, what failed, and why.

Comparative analysis
Enrollment efficiency
Your trial
COMP-A-2024
COMP-B-2023
COMP-C-2023
Success probability analysis
Your trial
85% High confidence
COMP-A-2024
75% High confidence
COMP-B-2023
68% High confidence
COMP-C-2023
60% High confidence
Key differentiators
Factor Your trial COMP-A-2024 COMP-B-2023
Protocol complexity Medium High Low
Site selection quality High Medium Medium
Patient population Broad Narrow Broad
Monitoring approach Risk-Based Traditional Risk-Based
Regulatory intelligence
75%
Compliance score
Identified issues
0 High risk
2 Medium risk
10 Low risk
Regulatory assessment
✓
21 CFR Part 312
Protocol includes clear primary and secondary objectives
Protocol meets regulatory standards for endpoints
⚠
FDA guidance for industry
Statistical analysis plan adequately defined
Enhance statistical analysis plan with interim calculations and justifications
✓
FDA guidance on eligibility criteria
Inclusion/exclusion criteria are clearly defined
Criteria are defined but could benefit from additional specificity
⚠
FDA guidance on safety Reporting
Safety monitoring and reporting procedures
Specify DSMB charter and safety monitoring protocol

Regulatory readiness
assessment

No more guessing. Predict what regulators will say before you submit, and fix issues while it's still early.

AI-assisted
protocol authoring

Let us be your co-author so your team can focus on the science, not paperwork.

💡 TrialOps AI recommendations
Smart insights based on historical trial data
High confidence
Sample size adjustment
Based on 8 similar trials in this indication, a larger sample size provides better statistical power. Recent trials averaged 25% more participants.
Based on 8 similar trials
Current: 120
Suggested: 170
Impact: Medium
High confidence
Additional secondary endpoint
Patient-reported outcomes are increasingly important for regulatory decisions. 70% of similar recently approved trials included QoL measures.
Based on 12 similar trials
Current: Progression-Free Survival (PFS), Overall Survival (OS), Duration of Response (DoR)
Suggested: Progression-Free Survival (PFS), Overall Survival (OS), Duration of Response (DoR), Quality of Life (QoL)
Impact: Medium
Medium confidence
Inclusivity improvement
Removing upper age restrictions increased enrollment rates by 15% in similar trials while maintaining safety profiles.
Based on 8 similar trials

Bringing treatments to life, one clinical trial at a time

We're building the intelligence layer that ensures promising treatments reach the patients who need them.

Our partners

NYU Entrepreneurial Institute Kurbside.co

Ready to change the odds?

Join the companies already using predictive intelligence to de-risk their clinical trials.